Bendtsen Marcus, McCambridge Jim
Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.
Department of Health Sciences, University of York, York, United Kingdom.
JMIR Res Protoc. 2019 Apr 18;8(4):e13119. doi: 10.2196/13119.
Harmful use of alcohol continues to be a leading contributor to premature deaths globally. Not only does harmful drinking have consequences for the individuals consuming at increased levels, but it may also result in a range of negative consequences for their family members and friends. Interventions delivered via mobile phones (mobile health [mHealth] interventions) could potentially support risky drinkers seeking help to reduce their alcohol consumption.
This protocol describes a randomized controlled trial that aims to validly estimate the effect of a novel mHealth intervention targeting risky drinkers in the general population of Sweden. Nested within the trial are 3 substudies that focus on methodological and user satisfaction research questions.
A 2-arm parallel group randomized controlled trial will be employed to estimate the effect of the novel intervention. Participants will be recruited through Web advertisements and social media. The inclusion criteria are as follows: 18 years or older, ownership of a mobile phone, and being classified as a risky drinker according to Swedish guidelines. Participants allocated to the intervention group will receive a novel mHealth intervention. The intervention consists of weekly screening, personalized feedback on current consumption, functions allowing for planning of future consumption, as well as a series of messages delivered throughout the week. Participants allocated to the control group will receive a short message regarding negative consequences of alcohol consumption and a hyperlink that offers more information. Following 2 and 4 months after randomization, both groups will be asked to complete follow-up questionnaires (2-month interval being primary). Primary outcomes are weekly alcohol consumption and heavy episodic drinking. Participants in the control group will be given access to the novel intervention after completing the 4-month follow-up. The trial includes 3 substudies: We will explore whether the mode of presenting information before participants giving informed consent affects participation rates and recall of trial parameters, investigate if the content of the short message received by the control group affects study outcomes and requests for more information, and explore user satisfaction with the intervention and reactions of the control group.
Participant recruitment is planned to begin in April 2019 and to last for a maximum of 24 months. The first dataset will be available approximately 2 months after the final participant has been recruited, and the final dataset will be available approximately 2 months later. No participants had been recruited at the time of submitting this protocol.
If found effective, the intervention has the potential to reduce negative consequences of alcohol consumption for individuals. The technology has been designed to have potential for extensive reach among those who may benefit.
ISRCTN Registry ISRCTN48317451; http://www.isrctn.com/ISRCTN48317451 (Archived by WebCite at http://www.webcitation.org/779tKLsu3).
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): PRR1-10.2196/13119.
有害饮酒仍然是全球过早死亡的主要原因之一。有害饮酒不仅会给饮酒量增加的个人带来后果,还可能给其家人和朋友带来一系列负面影响。通过手机进行的干预措施(移动健康[mHealth]干预)可能会帮助有饮酒风险的人寻求帮助以减少饮酒量。
本方案描述了一项随机对照试验,旨在有效评估一种针对瑞典普通人群中有饮酒风险者的新型移动健康干预措施的效果。该试验包含3项子研究,重点关注方法学和用户满意度方面的研究问题。
将采用双臂平行组随机对照试验来评估新型干预措施的效果。参与者将通过网络广告和社交媒体招募。纳入标准如下:年龄在18岁及以上、拥有手机且根据瑞典指南被归类为有饮酒风险者。分配到干预组的参与者将接受一种新型移动健康干预措施。该干预措施包括每周筛查、关于当前饮酒量的个性化反馈、用于规划未来饮酒量的功能以及在一周内发送的一系列信息。分配到对照组的参与者将收到一条关于饮酒负面影响的短信以及一个提供更多信息的超链接。随机分组后2个月和4个月,两组都将被要求完成随访问卷(以2个月间隔为主要时间点)。主要结局指标是每周饮酒量和大量饮酒事件。对照组的参与者在完成4个月随访后将可以使用新型干预措施。该试验包括3项子研究:我们将探讨在参与者给予知情同意前呈现信息的方式是否会影响参与率和对试验参数的记忆,调查对照组收到的短信内容是否会影响研究结局和对更多信息的需求,并探索用户对干预措施的满意度以及对照组的反应。
计划于2019年4月开始招募参与者,最长持续24个月。在最后一名参与者招募完成后约2个月可获得首个数据集,约2个月后可获得最终数据集。在提交本方案时尚未招募到任何参与者。
如果该干预措施被证明有效,有可能减少饮酒对个人的负面影响。该技术旨在有潜力惠及更多可能受益的人群。
国际标准随机对照试验编号ISRCTN48317451;http://www.isrctn.com/ISRCTN48317451(由WebCite存档于http://www.webcitation.org/779tKLsu3)。
国际注册报告识别号(IRRID):PRR1-10.2196/13119。